Cargando…
Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840691/ https://www.ncbi.nlm.nih.gov/pubmed/29552193 http://dx.doi.org/10.3892/ol.2018.8005 |
_version_ | 1783304625442521088 |
---|---|
author | Wang, Haohua Peng, Roujun Chen, Xiuxing Jia, Rui Huang, Chunyue Huang, Yuanyuan Xia, Liangping Guo, Guifang |
author_facet | Wang, Haohua Peng, Roujun Chen, Xiuxing Jia, Rui Huang, Chunyue Huang, Yuanyuan Xia, Liangping Guo, Guifang |
author_sort | Wang, Haohua |
collection | PubMed |
description | Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution were enrolled. Immunohistochemistry was used to detect HK2, PKM2 and LDHA expression. SPSS20 was used for statistical analysis. A total of 68 patients were included; 33 received cetuximab plus chemotherapy as first-line therapy, and the rest, as second- or later-line therapy. HK2 expression levels were increased in cancer compared with normal tissue (75.4% vs. 40%; P<0.001), however PKM2 (P=0.243) and LDHA (P=0.067) expression levels were not. For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021). However, this positive association was absent in 35 cases administered first-line chemotherapy alone (13.4 months vs. 13.5 months; P=0.539). LDHA expression was associated with the PFS of patients receiving first-line chemotherapy (18.3 and 10.1 months for high and low expression, respectively; P=0.005), whereas this association was absent in cetuximab plus chemotherapy cases (19.9 months vs. 12 months; P=0.522). Furthermore, high LDHA expression correlated with high overall response rate (ORR) (72.2% vs. 15.4%, P=0.006) for chemotherapy, however not disease control rate (DCR) (P=0.074). Neither DCR nor ORR were associated with HK2 expression. PKM2 expression did not affect PFS, DCR or ORR. LDHA expression (P=0.005), pathological differentiation (P=0.019) and synchronous/metachronous metastasis (P=0.014) were independent predictive factors of PFS for all first-line patients, and tumor differentiation (P=0.002) was associated with overall survival (OS) in multivariate analysis. HK2, PKM2 and LDHA did not impact OS. It was concluded that HK2 expression was increased in colorectal cancer tissue and may predict cetuximab efficacy and LDHA for chemotherapy treatment of mCRC. |
format | Online Article Text |
id | pubmed-5840691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-58406912018-03-16 Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer Wang, Haohua Peng, Roujun Chen, Xiuxing Jia, Rui Huang, Chunyue Huang, Yuanyuan Xia, Liangping Guo, Guifang Oncol Lett Articles Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution were enrolled. Immunohistochemistry was used to detect HK2, PKM2 and LDHA expression. SPSS20 was used for statistical analysis. A total of 68 patients were included; 33 received cetuximab plus chemotherapy as first-line therapy, and the rest, as second- or later-line therapy. HK2 expression levels were increased in cancer compared with normal tissue (75.4% vs. 40%; P<0.001), however PKM2 (P=0.243) and LDHA (P=0.067) expression levels were not. For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021). However, this positive association was absent in 35 cases administered first-line chemotherapy alone (13.4 months vs. 13.5 months; P=0.539). LDHA expression was associated with the PFS of patients receiving first-line chemotherapy (18.3 and 10.1 months for high and low expression, respectively; P=0.005), whereas this association was absent in cetuximab plus chemotherapy cases (19.9 months vs. 12 months; P=0.522). Furthermore, high LDHA expression correlated with high overall response rate (ORR) (72.2% vs. 15.4%, P=0.006) for chemotherapy, however not disease control rate (DCR) (P=0.074). Neither DCR nor ORR were associated with HK2 expression. PKM2 expression did not affect PFS, DCR or ORR. LDHA expression (P=0.005), pathological differentiation (P=0.019) and synchronous/metachronous metastasis (P=0.014) were independent predictive factors of PFS for all first-line patients, and tumor differentiation (P=0.002) was associated with overall survival (OS) in multivariate analysis. HK2, PKM2 and LDHA did not impact OS. It was concluded that HK2 expression was increased in colorectal cancer tissue and may predict cetuximab efficacy and LDHA for chemotherapy treatment of mCRC. D.A. Spandidos 2018-04 2018-02-08 /pmc/articles/PMC5840691/ /pubmed/29552193 http://dx.doi.org/10.3892/ol.2018.8005 Text en Copyright: © Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wang, Haohua Peng, Roujun Chen, Xiuxing Jia, Rui Huang, Chunyue Huang, Yuanyuan Xia, Liangping Guo, Guifang Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title_full | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title_fullStr | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title_full_unstemmed | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title_short | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer |
title_sort | effect of hk2, pkm2 and ldha on cetuximab efficacy in metastatic colorectal cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840691/ https://www.ncbi.nlm.nih.gov/pubmed/29552193 http://dx.doi.org/10.3892/ol.2018.8005 |
work_keys_str_mv | AT wanghaohua effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT pengroujun effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT chenxiuxing effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT jiarui effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT huangchunyue effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT huangyuanyuan effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT xialiangping effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer AT guoguifang effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer |